# Aichi Cancer Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/aichi-cancer-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 71.8 |
| Citations | 1,384,571 |
| City | Nagoya |
| Country | JP |
| Description | Aichi Cancer Center is a research organisation in Nagoya, JP. OpenAlex records 13,720 works and 1,384,571 citations for it. 1,442 researchers list it as their most recent affiliation. |
| Homepage | http://www.pref.aichi.jp/cancer-center/english/cc/ |
| OpenAlex ID | https://openalex.org/I4210133851 |
| Researchers | 1,442 |
| ROR ID | https://ror.org/03kfmm080 |
| Type | healthcare |
| Works | 13,720 |

## University papers

Showing 12 of 38.

- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2016-for/)
- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2019-for/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib](https://scholariq.org/papers/egfr-mediated-reactivation-of-mapk-signaling-contributes-to-insensitivity-of-i/)
- [Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort](https://scholariq.org/papers/antitumor-activity-of-pembrolizumab-in-biomarker-unselected-patients-with/)
- [Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-esmo-consensus-guidelines-for-the-management-of-patients-with/)
- [Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK](https://scholariq.org/papers/therapeutic-strategies-to-overcome-crizotinib-resistance-in-non-small-cell-lung/)
- [A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response](https://scholariq.org/papers/a-murine-lung-cancer-co-clinical-trial-identifies-genetic-modifiers-of/)
- [BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer](https://scholariq.org/papers/braf-mutation-is-a-powerful-prognostic-factor-in-advanced-and-recurrent/)
- [Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models](https://scholariq.org/papers/synthetic-lethal-interaction-of-combined-bcl-xl-and-mek-inhibition-promotes/)
- [Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92](https://scholariq.org/papers/apoptosis-induction-by-antisense-oligonucleotides-against-mir-17-5p-and-mir-20a/)

## University researchers

- [Hiromichi Ebi](https://scholariq.org/researchers/hiromichi-ebi/)
- [Yutaka Fujiwara](https://scholariq.org/researchers/yutaka-fujiwara/)

## University top topics

Showing 8 of 25.

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.